XML 76 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Information    
Interest income $ 331,849 $ 667,898
Net loss (24,590,375) (56,204,313)
Single reportable segment    
Segment Information    
Program expenses related to clinical-stage product candidates (16,723,518) (35,104,702)
Program expenses related to preclinical and discovery programs (568,214) (583,154)
Personnel-related expenses (including stock-based compensation) (6,525,586) (6,444,920)
General and administrative professional and consultant fees (1,687,276) (2,152,485)
Other segment items (1,190,333) (749,750)
Interest income 331,849 667,898
Other non-cash income (expense) items 1,772,704 (11,837,199)
Net loss $ (24,590,374) $ (56,204,313)